Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,160.31 +12.39 0.58%
FTSE 100 5,391.14 +34.80 0.65%
DAX 6,396.84 +73.65 1.16%
Ticker Volume Price Price Delta
Nikkei 8,633.19 -23.89 -0.28%
TOPIX 723.62 -3.41 -0.47%
Hang Seng 18,702.30 -353.12 -1.85%
Gold 1,552.50 +0.10%
EUR-USD 1.2477 -0.2089%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,391.14 +0.65%
STOXX 50 2,160.31 +0.58%
DAX 6,396.84 +1.16%
Oil (WTI) 90.34 -0.46%
U.S. 10-year 1.717% -0.027
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: SIX Swiss Ex
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Novartis AG

Add to Portfolio

NOVN:VX

50.200 CHF 0.280 0.56%

As of 11:30:32 ET on 05/29/2012.

Snapshot for Novartis AG (NOVN)

Open: 50.150 Day's Range: 50.000 - 50.450 Volume: 2,807,414 Bid: 50.200
Previous Close: 49.920 52wk Range: 38.910 - 55.050 1-Yr Rtn: -3.01% Ask: 50.250

Stock Chart for NOVN

No chart data available.
  • NOVN:VX 50.200
  • 1D
  • 1M
  • 1Y
49.920
Interactive NOVN Chart

Previous Close

Key Statistics for NOVN

Current P/E Ratio (ttm) 14.6034
Estimated P/E (12/2012) 9.5729
Earnings Per Share (USD) (ttm) 3.5700
Est. EPS (USD) (12/2012) 5.4460
Est. PEG Ratio 2.1283
Market Cap (M CHF) 135,850.89
Shares Outstanding (M) 2,706.19
Enterprise Value (M USD) (ttm) 160,291.15
Enterprise Value/EBITDA (ttm) 9.34
Price/Book (mrq) 1.9981
Price/Sale (ttm) 2.1513
Dividend Indicated Gross Yield 4.4821
Next Earnings Announcement 07/19/2012
More NOVN Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for NOVN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More NOVN Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More NOVN Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More NOVN Cash Flow Data

Company Profile & Key Executives for NOVN

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases, oncology, neuroscience, transplantation, dermatology, gastrointestinal and urinary conditions, and arthritis, vaccines and diagnostics, vision, and animal health products.

Daniel L VasellaChairmanUlrich LehnerCo-Vice Chairman
Joseph Jimenez Jr "Joe"Chief Executive OfficerJonathan R Symonds "Jon"Chief Financial Officer
More Company Profile & Key Executives for NOVN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements